Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and GSK on the list of drugmakers to pay to access the technology this year.
Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and GSK on the list of drugmakers to pay to access the technology this year.
